SuperworthDexCom EV/EBIT DXCM
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.
- Today, Oct 23, 2026
- 25.3×
- 7-year median
- 102×
- Against its 7-year history
- 1st
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 21.6× to 212×
- Peer median
- 22.6×
DexCom's EV/EBIT is 25.3× as of Oct 23, 2026.
That is below its 7-year median of 102×, lower than on 99% of days in the last 7 years.
Over that time it ranged from 21.6× in May 2026 to 212× in Jul 2020.
The median for 9 medical device stocks of a similar size is 22.6×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 25.3× | 21.6× | 37.6× |
| 2025 | 34.8× | 28.5× | 58.2× |
| 2024 | 50.4× | 37.1× | 90.9× |
| 2023 | 88.6× | 61.3× | 167× |
| 2022 | 163× | 102× | 193× |
| 2021 | 139× | 107× | 168× |
| 2020 | 117× | 99.5× | 212× |
Against its peers
Companies in Medical - Devices nearest DexCom's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| DXCMDexCom | 25.3× |
| GEHCGE HealthCare Technologies | 14.7× |
| ZBHZimmer Biomet | 21.5× |
| EWEdwards Lifesciences | 23.5× |
| BSXBoston Scientific | 18.2× |
| SYKStryker | 23.4× |
| MDTMedtronic | 20.7× |
| ABTAbbott Laboratories | 28.2× |
| LIVNLivaNova | 22.6× |
| ITGRInteger | 29.7× |
| Peer median | 22.6× |
Where DexCom ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on DexCom
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.